A Randomized Controlled Postoperative Adjuvant Chemotherapy Trial of MMC+Tegafur and MMC+UFT for Adenocarcinoma of the Lung-First Study (Second Report)

Abstract

The usefulness of adjuvant chemotherapy in patients with pulmonary carcinoma undergoing curative resection was jointly studied by 30- institutions in Wester Japan. The results of this trial after a 5-year follow-up are reported here.
The subjects were patients with pulmonary adenocarcinoma who underwent absolutely or relatively curative resection. They were treated with 20+10mg MMC, plus 600 mg tegafur orally for one year (Group A) or with 20+10mg MMC, plus 400-600mg UFT orally for one year (Group B). Between November 1982 and November 1985, 224 patients received this therapy (113 in Group A, and 111 in group B). Excluding 43 cases which were judged inappropriate for evaluation, 88 patients in Group A and 93 in Group B were evaluated. There was no significant difference in any background variable between the two groups.
The overall 5-year survival rate did not significantly differ between Group A (64.3%) and Group B (55.6%). The overall 5 year disease-free rate also did not significantly differ between the two groups. In stratified analysis, N2 cases in group B had higher 5 -year survival and recurrence-free rates than those in Group A (p=0.029 and 0.048, respectively).